Susan Lattimore

971 total citations
23 papers, 425 citations indexed

About

Susan Lattimore is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Susan Lattimore has authored 23 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 8 papers in Genetics and 5 papers in Oncology. Recurrent topics in Susan Lattimore's work include Hemophilia Treatment and Research (15 papers), Virus-based gene therapy research (8 papers) and CAR-T cell therapy research (5 papers). Susan Lattimore is often cited by papers focused on Hemophilia Treatment and Research (15 papers), Virus-based gene therapy research (8 papers) and CAR-T cell therapy research (5 papers). Susan Lattimore collaborates with scholars based in United States, Italy and Germany. Susan Lattimore's co-authors include Michael Recht, Steven Warach, Wolfgang Miesbach, Nigel S. Key, Frank W.G. Leebeek, Robert Gut, Annette von Drygalski, Giancarlo Castaman, Steven W. Pipe and Lawrence L. Latour and has published in prestigious journals such as New England Journal of Medicine, Blood and Stroke.

In The Last Decade

Susan Lattimore

21 papers receiving 408 citations

Peers

Countries citing papers authored by Susan Lattimore

Since Specialization

Citations

This map shows the geographic impact of Susan Lattimore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Lattimore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Lattimore more than expected).

Fields of papers citing papers by Susan Lattimore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Lattimore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Lattimore. The network helps show where Susan Lattimore may publish in the future.

Co-authorship network of co-authors of Susan Lattimore

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Lattimore. A scholar is included among the top collaborators of Susan Lattimore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Lattimore. Susan Lattimore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B 2025 ·New England Journal of Medicine ·Steven W. Pipe, Wolfgang Miesbach, Michael Recht, Frank W.G. Leebeek, Nigel S. Key, Giancarlo Castaman, Susan Lattimore, Michiel Coppens, Sandra Le Quellec, (unknown), Sean E. Gill, (unknown), Paul E. Monahan	0
2	Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years 2025 ·Blood Advances ·Annette von Drygalski, (unknown), Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan Lattimore, Frank W.G. Leebeek, Wolfgang Miesbach, Michael Recht, Paul E. Monahan, Sandra Le Quellec, Steven W. Pipe	3
3	Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up 2023 ·Hämostaseologie ·(unknown), (unknown), Michael Recht, (unknown), Susan Lattimore, Giancarlo Castaman, (unknown), (unknown), Robert Gut, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
4	Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities in health services; diversity, equity, and inclusion; and implementation science 2023 ·Expert Review of Hematology ·Vanessa R. Byams, Judith Baker, (unknown), Nathan T. Connell, Melissa Creary, Randall Curtis, Alexis Dinno, Christine Guelcher, Michelle Kim, Roshni Kulkarni, Susan Lattimore, (unknown), (unknown), Mark W. Skinner, (unknown), (unknown), (unknown), (unknown), (unknown), Tyler W. Buckner	8
5	Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy 2022 ·Blood Advances ·Annette von Drygalski, (unknown), Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan Lattimore, Frank W.G. Leebeek, Wolfgang Miesbach, Michael Recht, Robert Gut, Ricardo E. Dolmetsch, Paul E. Monahan, Sandra Le Quellec, Steven W. Pipe	40
6	Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up 2022 ·Blood ·Steven W. Pipe, Frank W.G. Leebeek, Michael Recht, Nigel S. Key, Susan Lattimore, Giancarlo Castaman, Michiel Coppens, (unknown), Robert Gut, (unknown), (unknown), (unknown), Yanyan Li, Paul E. Monahan, Wolfgang Miesbach	8
7	Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders 2021 ·Journal of Blood Medicine ·Leonard A. Valentino, Judith Baker, Regina B. Butler, Miguel A. Escobar, (unknown), (unknown), (unknown), Susan Lattimore, Diane J. Nugent, (unknown), Michael Recht, Mark T. Reding, (unknown), (unknown), Mark W. Skinner	27
8	Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes 2020 ·Research and Practice in Thrombosis and Haemostasis ·Stacy E. Croteau, Allison P. Wheeler, Osman Khan, Kristina M. Haley, Alexandra J. Borst, Susan Lattimore, Cindy H. T. Yeung, Alfonso Iorio	12
9	Dosing, Patient Satisfaction and Other Patient-Reported Outcomes after Switching to Rurioctocog Alfa Pegol in Athn 2: A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Coagulation Replacement Factor Products 2020 ·Blood ·Janna M. Journeycake, Michael Recht, Christine Guelcher, Ellis J. Neufeld, Margaret V. Ragni, Robert F. Sidonio, Cliff Takemoto, Michael D. Tarantino, Dunlei Cheng, Susan Lattimore, (unknown), (unknown)	1
10	Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B 2019 ·Blood Advances ·Annette von Drygalski, Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan Lattimore, Frank W.G. Leebeek, Wolfgang Miesbach, Michael Recht, Alison Long, Robert Gut, Eileen K. Sawyer, Steven W. Pipe	96
11	One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B 2019 ·Blood ·Steven W. Pipe, Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan Lattimore, Frank W.G. Leebeek, Wolfgang Miesbach, Michael Recht, (unknown), Alison Long, Robert Gut, Annette von Drygalski	11
12	Patient and Family Engagement during Treatment Change to Emicizumab at a Hemophilia Treatment Center 2019 ·Blood ·Susan Lattimore, (unknown)	0
13	Lack of Inhibitor Development in the American Thrombosis and Hemostasis Network (ATHN)-2 Factor Switching Study: Preliminary Report of Primary Outcome 2019 ·Blood ·Robert F. Sidonio, Dunlei Cheng, Christine Guelcher, Janna M. Journeycake, Susan Lattimore, Clifford M. Takemoto, Michael D. Tarantino, (unknown), Ellis J. Neufeld, (unknown)	1
14	Decreased Skeletal Health Negatively Impacts Quality of Life of People with Hemophilia 2018 ·Blood ·(unknown), Susan Lattimore, Jason Taylor	1
15	Goal Attainment Scaling for haemophilia (GAS‐Hēm): testing the feasibility of a new patient‐centric outcome measure in people with haemophilia 2018 ·Haemophilia ·Jonathan Roberts, Susan Lattimore, Michael Recht, Shannon Jackson, (unknown), S. Squire, Katherine Robinson, Victoria Price, (unknown), Sandra Richardson, Kenneth Rockwood	28
16	Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleeding 2017 ·Pediatric Research ·(unknown), (unknown), Anh T. P. Ngo, (unknown), (unknown), Susan Lattimore, Michael Recht, Owen J. T. McCarty, Kristina M. Haley	4
17	Assessment of neonatal platelet adhesion, activation, and aggregation 2016 ·Journal of Thrombosis and Haemostasis ·(unknown), Susan Lattimore, Michael Recht, Owen J. T. McCarty, Kristina M. Haley	39
18	Identification of Qualitative Platelet Disorders in Adolescent Women with Heavy Menstrual Bleeding 2016 ·Blood ·Kristina M. Haley, Susan Lattimore, (unknown), (unknown), (unknown), (unknown), Anh T. P. Ngo, Owen J. T. McCarty, Michael Recht	2
19	Silent Ischemic Lesion Recurrence on Magnetic Resonance Imaging Predicts Subsequent Clinical Vascular Events 2006 ·Archives of Neurology ·Dong‐Wha Kang, Susan Lattimore, Lawrence L. Latour, Steven Warach	49
20	Impact of Establishing a Primary Stroke Center at a Community Hospital on the Use of Thrombolytic Therapy 2003 ·Stroke ·Susan Lattimore, Julio A. Chalela, Lisa Davis, Thomas J. DeGraba, Mustapha A. Ezzeddine, Joseph Haymore, Paul Nyquist, Alison E. Baird, John M. Hallenbeck, Steven Warach	85

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact